Clinical impact of a pharmacist-physician co-managed programme on hyperlipidaemia management in Hong Kong

Area of Science:

• Cardiovascular Medicine
• Clinical Pharmacy
• Public Health

Background:

• Hyperlipidaemia poses a significant risk for cardiovascular diseases.
• Current management strategies often fall short of achieving target lipid levels for many patients.
• Optimizing lipid-lowering therapies requires effective patient monitoring and adherence support.

Purpose of the Study:

• To evaluate the clinical impact of a collaborative pharmacist-physician program on hyperlipidaemia management.
• To assess the effectiveness of co-managed care in improving patient lipid profiles.
• To determine if this integrated approach enhances achievement of low-density lipoprotein-cholesterol (LDL-C) goals.

Main Methods:

• Prospective randomized controlled trial involving adult patients with hyperlipidaemia not meeting LDL-C targets.
• Intervention group received pharmacist consultations on medication and lifestyle, with regular follow-ups.
• Control group received standard medical care.
• Primary outcome was the change in lipid panel parameters from baseline to study end.

Main Results:

• The study included 118 patients (58 intervention, 60 control) with similar baseline characteristics.
• The intervention group achieved significantly lower end-of-study LDL-C (2.80 +/- 0.89 mmol/L) and total cholesterol (4.75 +/- 1.08 mmol/L) compared to the control group (LDL-C: 3.24 +/- 0.78 mmol/L; total cholesterol: 5.18 +/- 0.93 mmol/L).
• These differences in lipid levels were statistically significant (P < 0.0015).

Conclusions:

• The pharmacist-physician co-managed program is effective in improving lipid profiles for hyperlipidaemic patients.
• This collaborative model significantly enhances the ability of patients to reach their target lipid levels.
• Integrating pharmacists into the care team offers a valuable strategy for optimizing cardiovascular risk management.